ALPHA3 Clinical Trial

Who Can Participate?

Here are the key qualifications you will need to meet to be eligible for the screening test portion of the ALPHA3 clinical study, known as MRD testing.

How Does This Screening Test Work?

The MRD test is a simple blood test designed to detect small amounts of cancer that remain in your body after treatment, at levels so low they can’t be detected by standard scans. Evidence of these trace levels is known as minimal residual disease (MRD), and testing positive (MRD+) may be an early indicator that you are at risk of having your cancer come back in the future, called relapse.

What Will Happen During the Clinical Trial?

The ALPHA3 clinical study has two steps. First, doctors will run the investigational MRD test to check if you still have any small amounts of cancer in your body at levels too small to be seen on a standard scan. If the test shows that you are MRD-, research indicates that your cancer is statistically unlikely to come back.

Are There Any Costs to Participate In This Study?

For qualified patients who participate in part one of the study, the investigational MRD test will be provided at no cost. For qualified patients who participate in part two of the study and subsequently enroll into the ALPHA3 clinical study treatment arm, the study treatment (CAR T-cell therapy) and study procedures that are not part of your standard of care will be provided at no cost.